Peripheral atherectomy — the mechanical removal of atherosclerotic plaque through directional cutting, laser ablation, rotational abrasion, or orbital mechanisms — represents the premium technology segment of peripheral vascular intervention, with the Peripheral Angioplasty Market reflecting atherectomy as a high-value procedural and device market.

Directional atherectomy — the Philips Spectranetics Turbo-Elite laser, Cardiovascular Systems Inc. (CSI) Diamondback Orbital Atherectomy System, Avinger Pantheris luminal imaging atherectomy, and Boston Scientific Jetstream — represent the diverse atherectomy technology approaches each with specific lesion type advantages. The CSI Diamondback orbital atherectomy achieving significant commercial success particularly for calcified lesion preparation before DCB or stent placement.

Calcium modification for DCB optimization — the emerging application of atherectomy for calcium debulking before drug-coated balloon delivery improving drug transfer efficiency in calcified lesions — represents the combination treatment rationale creating dual-procedure revenue. The REALITY trial and similar evidence demonstrating that calcified lesion preparation before DCB improves outcomes creating the procedural pairing that drives atherectomy plus DCB commercial adoption.

Intravascular lithotripsy (IVL) peripheral application — the Shockwave Medical peripheral IVL system using sonic pressure waves to fracture calcified plaque enabling balloon dilation of heavily calcified peripheral lesions — represents the novel calcium modification technology. The Shockwave peripheral IVL system's FDA clearance and growing peripheral adoption creating competition with atherectomy for the calcified peripheral lesion treatment market.

Do you think intravascular lithotripsy will eventually displace atherectomy for calcified peripheral lesion preparation, given its simpler technique and arguably safer profile compared to rotational or directional cutting devices?

FAQ

What peripheral atherectomy systems are available? Commercial peripheral atherectomy systems: CSI Diamondback 360 (orbital atherectomy — crown rotates eccentrically removing calcium); Philips Spectranetics Turbo-Elite (excimer laser — photoablation); Boston Scientific Jetstream (rotational plus aspiration — removes plaque and thrombus); Avinger Pantheris (directional with OCT imaging guidance); Medtronic Hawk (directional atherectomy, acquired from Covidien); each indicated for specific lesion types: orbital/laser for calcified; directional for eccentric plaque; each requiring specific operator training; atherectomy cost $3,000-6,000 per procedure plus angioplasty/stent cost.

What is intravascular lithotripsy (IVL) for peripheral arteries? Shockwave Medical IVL (peripheral): balloon catheter with lithotripsy emitters; sonic pressure waves fracture intimal and medial calcium; enables balloon dilation of resistant calcified lesions; multiple passes at low atmospheres; FDA cleared for peripheral arteries; advantages: familiar technique (like balloon angioplasty); no embolization risk from calcium debris (versus atherectomy); no tissue dissection; CE marked and FDA cleared; DISRUPT PAD trials supporting safety and efficacy; growing adoption for calcified SFA and below-knee lesions; commercial model: single-use IVL catheter approximately $2,500-3,500.

#PeripheralAngioplasty #Atherectomy #IntravascularLithotripsy #ShockwavePeripheral #CSIatherectomy #CalcifiedPAD